Becton, Dickinson and Company $BDX Stock Holdings Increased by Tidal Investments LLC

Tidal Investments LLC raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 22.4% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 146,408 shares of the medical instruments supplier’s stock after buying an additional 26,790 shares during the period. Tidal Investments LLC owned about 0.05% of Becton, Dickinson and Company worth $22,156,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Imprint Wealth LLC acquired a new position in shares of Becton, Dickinson and Company in the 3rd quarter worth $25,000. SHP Wealth Management purchased a new stake in shares of Becton, Dickinson and Company during the fourth quarter valued at $26,000. Meeder Asset Management Inc. lifted its holdings in shares of Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 102 shares during the last quarter. Main Street Group LTD acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at $29,000. Finally, Bell Investment Advisors Inc purchased a new position in Becton, Dickinson and Company in the 2nd quarter worth about $29,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on BDX. Bank of America lifted their target price on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Monday, August 31st. Jefferies Financial Group reissued a “buy” rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Stifel Nicolaus set a $195.00 price target on Becton, Dickinson and Company in a research report on Friday, August 7th. Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Finally, UBS Group started coverage on Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a “buy” rating and a $190.00 price objective for the company. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $187.67.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael Garrison sold 1,100 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. This represents a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 8,005 shares of company stock worth $1,423,580 over the last 90 days. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX opened at $176.18 on Friday. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The business’s 50 day moving average is $172.11 and its two-hundred day moving average is $160.53. The company has a market cap of $48.54 billion, a P/E ratio of 53.07, a P/E/G ratio of 12.67 and a beta of 0.21. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $193.07.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. Becton, Dickinson and Company’s revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a yield of 2.4%. Becton, Dickinson and Company’s dividend payout ratio is 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells products used by healthcare providers, researchers and pharmaceutical companies. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company is headquartered in Franklin Lakes, New Jersey.

BD’s products support medication delivery, infection prevention, diagnostics and surgical care. Its portfolio includes needles, syringes, injection devices, infusion products, medication-management systems, specimen-collection products, laboratory instruments and diagnostic technologies.